Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 28, 2013

View Archived Issues

Results presented for nanoliposomal irinotecan for the treatment of metastatic pancreatic cancer

The development of an optogenetic two-hybrid system for the control of mammalian gene transcription

Nuclear imaging of a novel radiolabeled probe for prostate cancer

Phase I study of GNX-5086 enrolls first healthy volunteer

Japanese researchers present new AMPA receptor modulators

Sareum Holdings patents novel agents for cancer

New cathepsin S and/or L inhibitors synthesized at Roche

Novel Der p 23 peptide-derived immunotherapy for house dust mite allergy

Researchers in China prepare new agents for HIV infection

Scientists in Germany disclose new agents for bacterial infections

Dainippon Sumitomo Pharma designs novel coagulation factor inhibitors

Subcutaneous Orencia launched in Japan for rheumatoid arthritis

Agenix and Arrayjet to jointly develop point-of-care diagnostic test

Spartan RX CYP2C19 assay receives FDA 510(k) clearance

Mount Sinai receives research grant for autism subtype study

BiondVax reports altered prime-boost strategy for its influenza vaccine

Orexigen receives DMC clearance to conduct interim analysis for the Light Study

OncoGenex reports Rainier trial initiation

Virttu Biologics treats first cohort in phase I/II mesothelioma study

Catalyst obtains FDA breakthrough therapy designation for Firdapse

Epilepsy treatment to be launched in Japan for partial-onset seizures

Health Canada approves Roche's Erivedge for advanced basal cell carcinoma

QRxPharma set to resubmit MoxDuo NDA

Medivir reports interim results from cohort 2 of COSMOS study

Bharat Biotech launches Typbar-TCV typhoid conjugate vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...